839P Matching-adjusted Indirect Comparison (MAIC) of Axicabtagene Ciloleucel (Axi-Cel) and Glofitamab (glofit) in Relapsed/refractory (R/R) Large B Cell Lymphoma (LBCL) after at Least Two Prior Systemic Therapies (3L+)
Annals of Oncology（2023）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined